-+ 0.00%
-+ 0.00%
-+ 0.00%

ST Bering (002424.SZ) subsidiary's application for clinical trial of innovative drug BD77 for inhalation was approved

Zhitongcaijing·08/31/2026 09:41:14
Listen to the news

Zhitong Finance App News, ST Bailing (002424.SZ) issued an announcement. Recently, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved by the State Drug Administration. The company's application for clinical trial of BD77 for inhalation was approved and agreed to carry out clinical trials for chronic obstructive pulmonary disease.

According to reports, BD77 for inhalation is a small molecule chemical with a purity of more than 98% obtained by separating and purifying a single legal Chinese herbal medicine. Pharmacological studies have shown that BD77 for inhalation was studied using a progressive strategy of “phenotypic pharmacodynamic clues - proteomics screening - target functional protein verification - target fishing - target binding verification - target dependency verification”, which suggests that it may act on inflammatory and tissue damage pathways associated with chronic obstructive pulmonary disease by activating endogenous inflammatory inhibitors, limiting excessive protease excretion, and maintaining pulmonary protease-antiprotease homeostasis.